A new method of producing NS5A antigen of hepatitis C virus
- Authors: Kuznetsova T.V.1,2, Smirnova M.S.1, Leonovich O.A.1, Gordeichuk I.V.1, Biriukova I.K.1, Zylkova M.V.1, Tyn’O Y.Y.1, Belyakova A.V.1, Shevelev A.B.1
-
Affiliations:
- Chumakov institute of Poliomyelitis and Viral Encephalitides
- National institute of Public Health Development
- Issue: Vol 62, No 1 (2017)
- Pages: 17-25
- Section: ORIGINAL RESEARCH
- Submitted: 20.01.2020
- Published: 20.02.2017
- URL: https://virusjour.crie.ru/jour/article/view/124
- DOI: https://doi.org/10.18821/0507-4088-2017-62-1-17-25
- ID: 124
Cite item
Full Text
Abstract
About the authors
T. V. Kuznetsova
Chumakov institute of Poliomyelitis and Viral Encephalitides; National institute of Public Health Development
Author for correspondence.
Email: noemail@neicon.ru
Russian Federation
M. S. Smirnova
Chumakov institute of Poliomyelitis and Viral Encephalitides
Email: noemail@neicon.ru
Russian Federation
O. A. Leonovich
Chumakov institute of Poliomyelitis and Viral Encephalitides
Email: noemail@neicon.ru
Russian Federation
I. V. Gordeichuk
Chumakov institute of Poliomyelitis and Viral Encephalitides
Email: noemail@neicon.ru
Russian Federation
I. K. Biriukova
Chumakov institute of Poliomyelitis and Viral Encephalitides
Email: kudykina_yuliya@mail.ru
Russian Federation
M. V. Zylkova
Chumakov institute of Poliomyelitis and Viral Encephalitides
Email: noemail@neicon.ru
Russian Federation
Ya. Ya. Tyn’O
Chumakov institute of Poliomyelitis and Viral Encephalitides
Email: noemail@neicon.ru
Russian Federation
A. V. Belyakova
Chumakov institute of Poliomyelitis and Viral Encephalitides
Email: noemail@neicon.ru
Russian Federation
A. B. Shevelev
Chumakov institute of Poliomyelitis and Viral Encephalitides
Email: noemail@neicon.ru
Russian Federation
References
- Benkovic S.J., Putney S.D., Schimmel P.R. Method for Degrading DNA. Patent USA № 4521509; 1985.
- Sugino Y., Morita M., Matuo Y., Uchida K. Method for Producing DNA Nested Deletions by an in Vitro Reaction Using Transposase. Patent USA № 6265159; 2001.
- Whitcomb J.M., Rashtchian A., Hughes S.H. A new PCR based method for the generation of nested deletions. Nucleic Acids Res. 1993; 21(17): 4143-6.
- Bouzgarrou N., Hassen E., Mahfoudh W., Gabbouj S., Schvoerer E., Ben Yahia A. et al. NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy. J. Med. Virol. 2009; 81(12): 2021-8.
- MacDonald A., Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J. Gen. Virol. 2004; 85(9): 2485-502.
- Muñoz de Rueda P., Casado J., Patón R., Quintero D., Palacios A., Gila A. et al. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses. J. Virol. 2008; 82(13): 6644-53.
- Noguchi T., Tamori A., Ogura N., Hori Y., Ikeda S., Nishiguchi S. Investigation of interferon-α response by a single amino acid substitution of nonstructural protein 5A in hepatitis C virus-infected patients. J. Interferon Cytokine Res. 2011; 31(8): 589-99.
- Sillanpää M., Melén K., Porkka P., Fagerlund R., Nevalainen K., Lappalainen M. et al. Hepatitis C virus core, NS3, NS4B and NS5A are the major immunogenic proteins in humoral immunity in chronic HCV infection. J.Virol. 2009; 6: 84.
- Desombere I., Van Vlierberghe H., Weiland O., Hultgren C., Sällberg M., Quiroga J. et al. Serum levels of anti-NS4a and anti-NS5a predict treatment response of patients with chronic hepatitis C. J. Med Virol. 2007; 79(6): 701-13.
- Swadling L., Capone S., Antrobus R.D., Brown A., Richardson R., Newell E.W. et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci. Transl. Med. 2014; 6(261): 261ra153.